Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -9.62% is 138% below its 5-year average of 25.36%, near the low end of its 5-year range (-9.62%–88.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 77.22% below its 12-month average of -5.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
-9.62%
RETURN ON EQUITY (ROE) AVG TTM
-5.43%
RETURN ON EQUITY (ROE) AVG 3Y
-3.13%
RETURN ON EQUITY (ROE) AVG 5Y
25.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.22%
CURRENT VS 3Y AVG
-207.07%
CURRENT VS 5Y AVG
-137.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-173.96%
vs the sector median at left
BioNTech SE
Market Cap
$24.69B
Return on Equity (ROE)
-9.62%
TTM Avg
-5.43%
3Y Avg
-3.13%
5Y Avg
25.36%
Market Cap
$25.29B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$23.82B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$25.81B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.25B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$26.40B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$21.15B
Return on Equity (ROE)
11.17%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$21.12B
Return on Equity (ROE)
20.48%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$29.23B
Return on Equity (ROE)
5.97%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $24.69B | -9.62% | -5.43% | -3.13% | 25.36% |
| Incyte Corporation (INCY)vs › | $25.29B | 25.41% | 12.92% | 11.29% | 9.83% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.82B | 18.89% | 16.95% | 19.08% | 20.56% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.81B | 14.13% | 13.34% | 14.07% | 18.07% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.25B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Labcorp Holdings Inc. (LH)vs › | $26.40B | 11.65% | 9.71% | 9.35% | 12.84% |
| STERIS plc (STE)vs › | $21.15B | 11.17% | 10.12% | 7.00% | 7.00% |
| United Therapeutics Corporation (UTHR)vs › | $21.12B | 20.48% | 18.68% | 17.25% | 16.03% |
| Medline Inc. (MDLN)vs › | $29.23B | 5.97% | 9.02% | 4.86% | 4.86% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.85B | 14.51% | 21.84% | 21.53% | 32.27% |
ROE
-9.6%
ROA
-8.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -9.62% |
| 2026-03-31 | -6.79% |
| 2025-12-31 | -5.73% |
| 2025-09-30 | -3.09% |
| 2025-06-30 | -1.91% |
| 2025-03-31 | -4.03% |
| 2024-12-31 | -3.56% |
| 2024-09-30 | -2.25% |
| 2024-06-30 | -2.59% |
| 2024-03-31 | 0.59% |
| 2023-12-31 | 4.53% |
| 2023-09-30 | 14.02% |
| 2023-06-30 | 20.83% |
| 2023-03-31 | 27.16% |
| 2022-12-31 | 46.76% |
| 2022-09-30 | 62.22% |
| 2022-06-30 | 74.62% |
| 2022-03-31 | 83.59% |
| 2021-12-31 | 88.25% |
| 2021-09-30 | 75.24% |
| 2021-06-30 | 74.30% |
| 2021-03-31 | 48.26% |
| 2020-12-31 | 2.63% |
| 2020-09-30 | -43.19% |
| 2020-06-30 | -37.89% |
| 2020-03-31 | -43.29% |
| 2019-12-31 | -36.23% |
| 2019-09-30 | -30.16% |
| 2019-06-30 | -30.03% |
| 2019-03-31 | -29.35% |
| 2018-12-31 | -18.59% |
